Real-World Treatment Preferences of Patients With Psoriatic Arthritis

At the American College of Rheumatology virtual annual meeting, researchers from the Hospital for Special Surgery (HSS) in New York City presented data on use of psoriatic arthritis (PsA) medications in real-world clinical practice, as well as patient preferences.

In this video courtesy of RheumNow.com, Olga Petryna, MD, of NYU Grossman School of Medicine in New York City, discusses the data and what patients valued most when making treatment decisions.

Following is a transcript of her remarks:

Today, I would like to talk about abstract #1810, which is a presentation from HSS on the prescribing trends and patient preferences in terms of biologic use in patients with psoriatic arthritis. While we see that the immunomodulatory therapies, TNF inhibitors, methotrexate, IL-17 inhibitors remain as a first choice of a medication, after the 2018 guideline update, we see that there’s a significant increase in percentage of patients who choose interleukin-17 inhibitors as their first line of treatment for psoriatic arthritis. We went up from 3.5 to 30%, and a similar trend is seen for anti-PDE4 inhibitors, Otezla [apremilast] in particular, where it went from 11% to 40% patients choosing as a first line treatment.

Of course, there’s still a lot of use of … first-line anti-TNF inhibitors, but there is a little bit of the shift in other treatment options preferred by the patients. And then when patients were surveyed and asked, like, what’s the most extreme importance for them when they choose medication, they said prevention of the joint damage at 80%, perform daily activities at 71%, prevention of pain and doctor’s choice between 60 to 70%, and, of course, medication side effects were rated at 62%.

So it seemed that choice of the medication is important for the patient. And what is most concerning for them is safety of the medication and prevention of joint damage, and that probably leads to this particular increase in IL-17 inhibitor use.

Please enable JavaScript to view the comments powered by Disqus.